My lung cancer journey
LabTalk blog post by Dr Denny Clifford - “Early in my career as a practicing Pulmonary and Critical Care specialist I was fortunate to be a Principal Investigator on an AstraZeneca study, which led to a long relationship investigating new pharmaceuticals in the Respiratory field. In my 33 years as a practicing doctor I have diagnosed over 800 lung cancers, and dedicated my time to providing patients with the best possible care.”
Lung Cancer Awareness Month: Spreading the Word about Scientific Advances
November is Lung Cancer Awareness Month; an important occasion when we can pause to reflect on valuable diagnostic and treatment advances in our journey to improving cancer outcomes. These scientific discovery milestones continue to excite me, along with the wider scientific community, and provide hope to patients and their loved ones.
Harnessing personalised healthcare to identify novel therapeutic targets for Chronic Kidney Disease (CKD) patients
Each November, more than 13,000 leading nephrologists and other medical and scientific professionals from around the world present and discuss the latest advances and challenges in kidney research and treatment at the American Society of Nephrology Kidney Week. This year, with a steadily growing presence, AstraZeneca is presenting five abstracts from our early science research teams alone that unveil new evidence for novel, potential chronic kidney disease (CKD) drug targets that leverage our personalised healthcare approach.
AstraZeneca climbs eight positions in Access to Medicine Index
The highest climber in the 2016 Index, AstraZeneca is now ranked seventh overall in providing access to medicine. The Access to Medicines Index ranks the top 20 pharmaceutical companies based on their access-to-medicine performance for high-burden diseases in low- and middle-income countries.
AstraZeneca recognised as world leader for corporate action on climate change
AstraZeneca is among 9% of corporations participating in CDP’s climate change programme to be awarded a position on the Climate A List. AstraZeneca is also one of only four FTSE 350 companies to have had its climate change targets approved by the Science Based Targets (SBT) initiative. SBT is a partnership with CDP, the UN Global Compact (UNGC), World Resources Institute (WRI), and World Wide Fund for Nature (WWF). The initiative seeks to create a systematic change in how targets are set, so that companies contribute their fair share of the challenging emissions reduction needed to limit global temperature increase to under two degrees centigrade. The CDP considers targets approved by the SBT initiative to reflect best practice in climate change target setting.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
We partner with others around the world, combining the great science in our labs with complementary technologies, know-how and molecules to accelerate the delivery of new life-changing medicines.
Page Atlas ID: 970733.011.
Date of next review: April 2017